FDA OKs four Illumina gene-sequencing devices

Illumina (ILMN) has received approval for four "next-generation" gene-sequencing devices that have the potential to make quicker and more accurate diagnoses of cystic fibrosis,

The tests will search for "the largest number of cystic fibrosis gene variations that we've ever cleared a test for," the FDA's Elizabeth Mansfield said.

Two of the tests also have potential to be used to diagnose and treat certain genetically identifiable cancers. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs